SOUTH SAN FRANCISCO, Calif., May 21 Exelixis,Inc. (Nasdaq: EXEL) announced today that it will hold an investor and analystbriefing in conjunction with the 44th Annual Meeting of the American Societyof Clinical Oncology (ASCO) from 6:00 p.m. to 8:00 p.m. CT on Monday, June 2,2008.
The event will be webcast and may be accessed in the Event Calendar pageunder Investors at http://www.exelixis.com.
An archived replay of this webcast will be available until 9:00 p.m.PT/12:00 a.m. ET on July 2, 2008. Access numbers for this replay are: 1-888-286-8010 (domestic) and +1-617-801-6888 (international); the replay passcodeis: 42662164.
Exelixis, Inc. is a development-stage biotechnology company dedicated tothe discovery and development of novel small molecule therapeutics for thetreatment of cancer and other serious diseases. The company is leveraging itsfully integrated drug discovery platform to fuel the growth of its developmentpipeline, which is primarily focused on cancer. Currently, Exelixis' broadproduct pipeline includes investigational compounds in phase 2 and phase 1clinical development. Exelixis has established strategic corporate allianceswith major pharmaceutical and biotechnology companies, includingGlaxoSmithKline, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals andDaiichi-Sankyo. For more information, please visit the company's web site athttp://www.exelixis.com.
Exelixis and the Exelixis logo are registered U.S. trademarks.Participants: -- George A. Scangos, PhD, President and Chief Executive Officer -- Michael M. Morrissey, PhD, President of Research and Development -- Gisela M. Schwab, MD, Executive Vice President and Chief Medical Officer Topics: -- XL184 (targets: MET, VEGFR2, RET) -- XL147 (targets: PI3K) -- XL765 (targets: PI3K, mTOR) -- XL647 (targets: EGFR, HER2, VEGFR2) -- XL880* (targets: MET, VEGFR2) -- XL281 (targets: RAF) * XL880 was selected by GlaxoSmithKline in December 2007 for further development and commercialization.
SOURCE Exelixis, Inc.